Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Rodney H Falk, MD, Morie A Gertz, MD, Merrill D Benson, MD, Gustavo Buchele, MD PhD, Michela Brambatti, MD MS, Sotirios Tsimikas, MD, Nicholas J Viney, Bsc, Li-Jung Tai, MD PhD, Cecilia Monteiro, MD PhD, Qingqing Yang, MS, Louis St L O'Dea, MB B.Ch. BAO, FRCP, Ewa Karwatowska-Prokopczuk, MD PhD, Eugene Schneider, MD, Richard S Geary, PhD, Brett P Monia, PhD

Blood (2019) 134 (Supplement_1): 5764.

https://doi.org/10.1182/blood-2019-129269

Published: 2019

Journal Articles

Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis

Marco Basset, MD, Paolo Milani, MD PhD, Andrea Foli, MD, Mario Nuvolone, MD PhD, Jessica Ripepi, Margherita Bozzola, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 3312.

https://doi.org/10.1182/blood-2019-130364

Published: 2019

Journal Articles

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Shayna Sarosiek, John Mark Sloan, MD, Karen Quillen, MDMPH, Dina Brauneis, ANP, Ramon Cruz, Amanda Schulman, Salli Fennessey, Anthony Shelton, Vaishali Sanchorawala, MD

Blood (2019) 134 (Supplement_1): 4578.

https://doi.org/10.1182/blood-2019-129095

Published: 2019

Journal Articles

Clinical Characteristics and Outcome of Patients with Wild-Type Transthyretin and AL Cardiac Amyloidosis Confirmed By Mass Spectrometry

Stephen Parkin, MD BSc, Michael A. Seidman, MD FRCPC, Margot Davis, MD FRCPC, Kevin Song, MD

Blood (2018) 132 (Supplement 1): 3126.

https://doi.org/10.1182/blood-2018-99-115317

Published: 2018

Journal Articles

Novel Cardiac Biopsy Scoring Tool to Predict Clinical Outcomes in Cardiac Light Chain (AL) Amyloidosis

Ujjawal H Gandhi, PhDMBBS, Hanna Von Haefen, Robert Hoffman, MD PhD, Alexandra Ritts, MD, Sharon Phillips, MSPH, Oluchi Ukaegbu, MD, Samuel Rubinstein, MD, Shelton Lacy Harrell, MSN, Stacey A. Goodman, MD MS, Daniel Lenihan, MD, David Slosky, MD, Rebecca Hung, MD PhD, Robert Frank Cornell, MD

Blood (2017) 130 (Supplement 1): 1881.

https://doi.org/10.1182/blood.V130.Suppl_1.1881.1881

Published: 2017

Journal Articles

Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation

Blood (2017) 130 (Supplement 1): 1815.

https://doi.org/10.1182/blood.V130.Suppl_1.1815.1815

Published: 2017

Journal Articles

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Blood (2016) 128 (22): 646.

https://doi.org/10.1182/blood.V128.22.646.646

Published: 2016

Journal Articles

HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Al Amyloidosis

Monique Minnema, Kazem Nasserinejad, MA, Bouke Hazenberg, MD PhD, Ute Hegenbart, Lucien Noens, MD PhD, Paula F. Ypma, MD, Sonja Zweegman, MD PhD, Lidwine Winnifred Tick, MD PhD, Annemiek Broijl, MD PhD, Harry R. Koene, MD PhD, Gerard M.J. Bos, MD PhD, Pieter Sonneveld, MD PhD, Stefan O. Schoenland, MD

Blood (2016) 128 (22): 4628.

https://doi.org/10.1182/blood.V128.22.4628.4628

Published: 2016

Journal Articles

Six-Minute Walk Test As a Measure of Functional Change after Chemotherapy in Cardiac AL Amyloidosis

Ilka Decker, MD MS, Oluchi C. Ukaegbu, MD, Stacey A. Goodman, MD MS, Daniel J. Lenihan, MD, Rebecca R Hung, MD, Adetola A. Kassim, MD MS, Shelton L. Harrell, MSN, ACNP-BC, Kevin McDonagh, MD, Sharon E. Phillips, MSPH, Kyle T Rawling, Samuel M Rubinstein, MD, Tarsheen K. Sethi, MD MS, Robert F Cornell, MD MS

Blood (2015) 126 (23): 1841.

https://doi.org/10.1182/blood.V126.23.1841.1841

Published: 2015

Journal Articles

Updated Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Suzanne Lentzsch, MD PhD, Raymond L. Comenzo, MD, Jeffrey A Zonder, MD, Keren Osman, MD, Miao Susanna, Daniel Backenroth, Daniel Otap, Wei-Yann Tsai, Siva Pregja, Shahzad Raza, MD, Vaishali Sanchorawala, MD, Heather J Landau, MD

Blood (2015) 126 (23): 3041.

https://doi.org/10.1182/blood.V126.23.3041.3041

Published: 2015

Journal Articles

Patients with AL Amyloidosis and Low Free Light Chain Burden Have Distinct Clinical Features and Outcome

Paolo Milani, MD, Andrea Foli, MD, Marco Basset, MD, Giovanni Palladini, MD PhD, Giampaolo Merlini, MD

Blood (2015) 126 (23): 1773.

https://doi.org/10.1182/blood.V126.23.1773.1773

Published: 2015

Journal Articles

A Prospective Study of Treatment Outcomes in 179 Patients with Advanced Cardiac Stage STAGE IIIb Amyloidosis

Belen Sevillano, Haematology Specialist, Ashutosh Wechalekar, MDFRCPath FRCP, Darren Foard, Specialist Nurse, Carol Whelan, MDFRCP, Marianna Fontana, MD, Cristina Quarta, Shameem Mahmood, FRCPath, Helen Lachmann, MDFRCP, Julian D Gillmore, MDPhDFRCP, Philip N Hawkins, MDPhDFMedSci

Blood (2015) 126 (23): 5357.

https://doi.org/10.1182/blood.V126.23.5357.5357

Published: 2015

Journal Articles

A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Adam D. Cohen, MD, Emma C. Scott, MD, Michaela Liedtke, MD, Jonathan L. Kaufman, MD, Heather Landau, MD, David H. Vesole, MD PhD, Christina L. Gomes, MD, Cristina Gasparetto, MD, Suzanne Lentzsch, MD PhD, Michael Rosenzweig, MD, Vaishali Sanchorawala, MD, David D. Smith, PhD, Raymond L. Comenzo, MD, Brian G. M. Durie, MD

Blood (2014) 124 (21): 4741.

https://doi.org/10.1182/blood.V124.21.4741.4741

Published: 2014

Journal Articles

A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease

Jeffrey Zonder, MD, Christiane Houde, BS, Sascha Tuchman, MD, Vishal Kukreti, MD, Vaishali Sanchorawala, MD, Silva Pregja, MBA, Kathy A Reichel, Steven M Burt, NP, Colleen Neveux, RN, Jeffrey Matous, MD

Blood (2014) 124 (21): 4767.

https://doi.org/10.1182/blood.V124.21.4767.4767

Published: 2014

Journal Articles

Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light Chain (AL) Amyloidosis

Suzanne Lentzsch, MD PhD, Raymond L. Comenzo, MD, Keren Osman, MD, Kevin Zikaras, BS, Daniel Backenroth, Wei-Yann Tsai, Vaishali Sanchorawala, MD, Heather Landau, MD

Blood (2014) 124 (21): 3480.

https://doi.org/10.1182/blood.V124.21.3480.3480

Published: 2014

Journal Articles

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Blood (2014) 124 (21): 35.

https://doi.org/10.1182/blood.V124.21.35.35

Published: 2014

Journal Articles

Increased Bone Marrow Plasma Cells at Diagnosis Predicts Overall Mortality in AL Amyloidosis Patients Undergoing Risk-Adapted Stem Cell Transplant

Chrystal A. Landry, MD, Melody Smith, MD, Joanne F. Chou, Sean M. Devlin, PhD, Hani Hassoun, MD, Christina Bello, Ola Landgren, MD PhD, Sergio Giralt, MD, Raymond L. Comenzo, MD, Heather Landau, MD

Blood (2014) 124 (21): 2522.

https://doi.org/10.1182/blood.V124.21.2522.2522

Published: 2014

Journal Articles

Safety Profile Of Bortezomib Impacts Survival Of Cardiac AL Amyloidosis

Zoé Van de Wyngaert, MD, Greg Vanoutryve, Charles Herbaux, MD, Guillemette Fouquet, MD, Helene Demarquette, MD, Sarah Bonnet, MD, David Beauvais, MD, Stéphanie Guidez, MD, Nicolas Lamblin, MD, Eric Hachulla, MD, PhD, David Launay, Louis Terriou, MD, Bénédicte Hivert, MD, Mathieu Wemeau, MD, Xavier Leleu, MD, PhD

Blood (2013) 122 (21): 5316.

https://doi.org/10.1182/blood.V122.21.5316.5316

Published: 2013

Journal Articles

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

Blood (2013) 122 (21): 3187.

https://doi.org/10.1182/blood.V122.21.3187.3187

Published: 2013

Journal Articles

Six-Year Follow-Up Of Dasatinib-Related Pulmonary Arterial Hypertension (PAH) For Chronic Myeloid Leukemia In Single Center

Young-Woo Jeon, M.D., Sung-Eun Lee, M.D., Soo-Hyun Kim, Soo-Young Choi, Jin-Eok Park, Hye-Rim Jeon, Eun-Jung Jang, Dong-Wook Kim, MD, PhD

Blood (2013) 122 (21): 4017.

https://doi.org/10.1182/blood.V122.21.4017.4017

Published: 2013

NARROW

Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Clinical Characteristics and Outcome of Patients with Wild-Type Transthyretin and AL Cardiac Amyloidosis Confirmed By Mass Spectrometry

Novel Cardiac Biopsy Scoring Tool to Predict Clinical Outcomes in Cardiac Light Chain (AL) Amyloidosis

Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Al Amyloidosis

Six-Minute Walk Test As a Measure of Functional Change after Chemotherapy in Cardiac AL Amyloidosis

Updated Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Patients with AL Amyloidosis and Low Free Light Chain Burden Have Distinct Clinical Features and Outcome

A Prospective Study of Treatment Outcomes in 179 Patients with Advanced Cardiac Stage STAGE IIIb Amyloidosis

A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis

A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease

Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light Chain (AL) Amyloidosis

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Increased Bone Marrow Plasma Cells at Diagnosis Predicts Overall Mortality in AL Amyloidosis Patients Undergoing Risk-Adapted Stem Cell Transplant

Safety Profile Of Bortezomib Impacts Survival Of Cardiac AL Amyloidosis

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

Six-Year Follow-Up Of Dasatinib-Related Pulmonary Arterial Hypertension (PAH) For Chronic Myeloid Leukemia In Single Center

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only